http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Thomas Bartl,Christine Bekos,Magdalena Postl,Reinthaller Alexander,Stephan Polterauer,Aust Stefanie,Schwameis Richard 대한부인종양학회 2021 Journal of Gynecologic Oncology Vol.32 No.1
Objective: To assess the prognostic value of the systemic immune-inflammation index (SII)in patients with vulvar cancer. Methods: Data of 130 consecutive patients who underwent primary surgical resection forvulvar cancer at the Medical University of Vienna between 1999 and 2018 was retrospectivelyanalyzed. The SII was defined as platelets × neutrophils/lymphocytes as previously described. Its prognostic value on disease-specific survival (DSS) and overall survival (OS) was evaluatedby univariate log-rank tests and multivariable cox regression models. Prediction accuracy wasassessed by receiver operating characteristics curves and Youden's J statistics. A Hosmer Lemeshow test was performed to confirm the model's goodness of fit. Results: A pre-therapeutic high serum SII (>866.4) was associated with advancedInternational Federation of Gynecology and Obstetrics (FIGO)-stage. In univariate survivalanalysis, a high SII was associated with both DSS (p<0.001) and OS (p=0.001). A multivariatecox regression model confirmed the prognostic value of SII regarding DSS (p<0.001) and OS(p=0.014) independently from patients' age and FIGO stage. Conclusions: Pretherapeutic SII may serve as a promising predictor for survival in patientswith vulvar cancer. After clinical validation, the SII may be used to improve both pre treatment patient risk stratification and patient counseling.